Drugs / RLD2202
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05548543 | Oct → Dec 2022 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT05548387 | Sep → Nov 2022 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT05481307 | Aug → Oct 2022 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RLD2202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05548387 ↗ |